Eli Lilly Voices Concerns Over Proposed Pharmaceutical Tariffs
Table of Contents
The drugmaker warns of potential increases in drug costs and restricted patient access.
By Amelia Stone | WASHINGTON D.C.- 2025/08/17 13:34:10
Eli Lilly has publicly opposed proposed tariffs on pharmaceuticals, warning that such measures could lead to increased drug costs and limit patient access to essential medications.
The pharmaceutical company stated that it has invested over $50 billion in U.S. manufacturing as 2020. this includes 10 projects specifically aimed at ensuring the domestic market is supplied entirely from within the United States, according to a news release issued on August 14.
Recently, President Donald Trump floated the idea of imposing tariffs on pharmaceutical imports, potentially as high as 250%. This proposal is part of a broader initiative to encourage more drug manufacturing within the U.S.
While supporting efforts to create a more equitable global drug pricing system,Eli lilly advocates for reforms that address systemic issues within the U.S. market. These issues include complex pricing structures, insurance cost-sharing arrangements, and the misuse of programs like 340B.The company believes these reforms should be pursued without resorting to tariffs.
The drugmaker is also collaborating with governments in other countries, including an agreement with the U.K. to increase the price of Mounjaro.These efforts are part of a strategy to raise drug prices internationally while advocating for lower prices in the U.S., according to the release.
Impact of Pharmaceutical Tariffs
Pharmaceutical tariffs could have a wide-ranging impact on the healthcare industry and patients. These tariffs, essentially taxes on imported drugs, could disrupt supply chains and increase the cost of medications for consumers.
“They could increase drug costs and restrict patient access.”
Understanding Pharmaceutical Tariffs and Drug Pricing
